Janet Thomas
Clinical Genetics (M.D.) · Aurora, CONPI 1225113954
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (38.5%), consulting fees and education — rather than concentrated in one kind of arrangement. Biomarin Pharmaceutical Inc. accounts for 64.2% of it on its own, with 5 other manufacturers making up the rest.
Across 106 payments — averaging $621.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biomarin Pharmaceutical Inc.$42K
- Travere Therapeutics, Inc.$11K
- PTC Therapeutics, Inc.$10K
- Sanofi$1K
- Applied Therapeutics, Inc.$900
- Ultragenyx Pharmaceutical Inc.$30
Across 176 payments — averaging $13,011 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Travere Therapeutics, Inc.$845K
- Biomarin Pharmaceutical Inc.$656K
- Ultragenyx Pharmaceutical Inc.$441K
- PTC Therapeutics, Inc.$196K
- Sanofi$77K
- Applied Therapeutics, Inc.$60K
- plus $15K from 2 others
What the payments were for
- Consulting fees$22,29234%
- Speaking & faculty fees$25,40039%
- Travel & lodging$6,39310%
- Food & beverage$2,3834%
- Education$9,45814%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biomarin Pharmaceutical Inc. | 66 | $42,337 |
| Travere Therapeutics, Inc. | 16 | $11,172 |
| PTC Therapeutics, Inc. | 11 | $10,431 |
| Sanofi | 11 | $1,055 |
| Applied Therapeutics, Inc. | 1 | $900 |
| Ultragenyx Pharmaceutical Inc. | 1 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Palynziq$36,730
- Kuvan$14,527
- SEPHIENCE$5,604
- NO PRODUCT DISCUSSED$664
How this compares
Too few clinical genetics (m.d.) providers in Coloradoto place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PalynziqPegvaliase-Pqpz | 18 | $595,653 |
| AldurazymeLaronidase | 13 | $507,454 |
| KuvanSapropterin Dihydrochloride | 11 | $264,962 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Biomarin Pharmaceutical Inc.Palynziq, Kuvan | $42,337 | $860,61529 claims |
| SanofiAldurazyme | $1,055 | $507,45413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical genetics (m.d.) providers in Coloradoon file to place this against a meaningful peer group, so we don't.
Other clinical genetics (m.d.) in Aurora
- Matthew TaylorAurora$41K
- Shawn McCandlessAurora$33K
- Jessica DuisAurora$25K
- Austin LarsonAurora$22K
- Aaina KochharAurora$11K
- Peter BakerAurora$7K
- Margarita SaenzAurora$2K
- Johan van HoveAurora$117
- Farrah RajabiAurora$26
- Naomi MeeksAurora$25
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.